This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TTNP Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Titan Pharmaceuticals Stock (NASDAQ:TTNP) Get Titan Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.55▼$4.8050-Day Range$3.64▼$5.9352-Week Range$3.53▼$5.76Volume3.10 million shsAverage Volume76,658 shsMarket Capitalization$7.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Titan Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules. The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas. In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.AI Generated. May Contain Errors. Read More Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TTNP Stock News HeadlinesTitan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan CorporationOctober 3, 2025 | globenewswire.comTitan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all. | Porter & Company (Ad)TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comTitan Pharmaceuticals Inc (TTNP) - Investing.comJuly 4, 2025 | investing.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29, 2025 | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29, 2025 | nasdaq.comSee More Headlines TTNP Stock Analysis - Frequently Asked Questions How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its earnings results on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TTNP CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees10Year Founded1992Profitability EPS (Trailing Twelve Months)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.60% Return on Assets-95.64% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book2.22Miscellaneous Outstanding Shares1,330,000Free Float1,320,000Market Cap$7.88 million OptionableOptionable Beta1.37 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TTNP) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredIt's time to "buy the dip" in goldGold just posted a significant correction - and one analyst calls it the biggest buy-the-dip opportunity of th...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
